What is the official website of ORSCoslyte ?

The official website of ORSCoslyte is http://www.orscoslyte.com.

What is ORSCoslyte's cybersecurity risk score?

ORSCoslyte has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has ORSCoslyte experienced?

According to Rankiteo, ORSCoslyte currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has ORSCoslyte been affected by any supply chain cyber incidents ?

According to Rankiteo, ORSCoslyte has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does ORSCoslyte have SOC 2 Type 1 certification ?

According to Rankiteo, ORSCoslyte is not certified under SOC 2 Type 1.

Does ORSCoslyte have SOC 2 Type 2 certification ?

According to Rankiteo, ORSCoslyte does not hold a SOC 2 Type 2 certification.

Does ORSCoslyte comply with GDPR ?

According to Rankiteo, ORSCoslyte is not listed as GDPR compliant.

Does ORSCoslyte have PCI DSS certification ?

According to Rankiteo, ORSCoslyte does not currently maintain PCI DSS compliance.

Does ORSCoslyte comply with HIPAA ?

According to Rankiteo, ORSCoslyte is not compliant with HIPAA regulations.

Does ORSCoslyte have ISO 27001 certification ?

According to Rankiteo,ORSCoslyte is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does ORSCoslyte operate in ?

ORSCoslyte operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does ORSCoslyte have ?

ORSCoslyte employs approximately None employees people worldwide.

Does ORSCoslyte own any subsidiaries ?

ORSCoslyte presently has no subsidiaries across any sectors.

How many LinkedIn followers does ORSCoslyte have ?

ORSCoslyte's official LinkedIn profile has approximately 150 followers.

What is the NAICS classification code for ORSCoslyte ?

ORSCoslyte is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does ORSCoslyte have a Crunchbase profile ?

No, ORSCoslyte does not have a profile on Crunchbase.

Does ORSCoslyte have a LinkedIn profile ?

Yes, ORSCoslyte maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/orscoslyte.

How many cybersecurity incidents has ORSCoslyte experienced ?

As of June 13, 2026, Rankiteo reports that ORSCoslyte has not experienced any cybersecurity incidents.

How many peer or competitor companies does ORSCoslyte have ?

ORSCoslyte has an estimated 5,686 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

ORSCoslyte

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

ORSCoslyte Vendor Cyber Rating & Cyber Score

orscoslyte.com

Add Your Compliance Badge

Coslyte is a leading ORS brand in India, known for its WHO recommended formulation of 245 mOsm/L1 to fight dehydration instantly. With the right proportion of Sodium Chloride, Potassium Chloride, Sodium Citrate and Dextrose Anhydrous, Coslyte ORS replenishes the body with electrolytes, making it the ideal choice to combat diarrhoeal diseases and dehydration. Coslyte ORS powder is available in 21gms and 4.2 grams sachets, in refreshing orange and lemon flavours, whereas Coslyte RTD is available in 200ml bottles in Orange Flavour. It’s a brand of Oaknet Lifesciences which was launched in April 2015 by R S Raghav and a distinguished team of experts combining 150 years of experience, significant achievements & status amongst the top 10

ORSCoslyte A.I CyberSecurity Scoring

Scoring History

ORSCoslyte

ORSCoslyte CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

ORSCoslyte Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for ORSCoslyte

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for ORSCoslyte in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for ORSCoslyte in 2026.

Incident Types ORSCoslyte vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for ORSCoslyte in 2026.

Incident History - ORSCoslyte (X = Date, Y = Severity)

Loading…

SUBSIDIARY

ORSCoslyte Subsidiaries

ORSCoslyte

Pharmaceutical Manufacturing

Website: http://www.orscoslyte.com

Company Size: 1,001-5,000 employees

Samara CapitalVenture Capital and Private Equity Principals

More Retail Private LimitedRetail

Sapphire Foods India LimitedRestaurants

Affluent Global ServicesIT Services and IT Consulting

SPOTON LOGISTICS PVT LTDTransportation, Logistics, Supply Chain and Storage

Life@SpotonTransportation, Logistics, Supply Chain and Storage

FirstMeridian Business Services LimitedHuman Resources Services

FirstMeridian ProfessionalHuman Resources Services

TI MedicalMedical Equipment Manufacturing

Esme ConsumerPersonal Care Product Manufacturing

Blue Heaven CosmeticsPersonal Care Product Manufacturing

SMS Integrated Facility ServicesFacilities Services

InnovsourceStaffing and Recruiting

V5 GlobalStaffing and Recruiting

Eris Oaknet Healthcare Pvt. Ltd.Pharmaceutical Manufacturing

Loading…

ORSCoslyte Similar Companies

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Novo Nordisk

novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Loading…

NEWS

ORSCoslyte CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-6676

SUMMARY

Heap buffer out-of-bounds write vulnerability in Avira Antivirus engine when scanning a malformed POSIX tar archive may allow Local Execution of Code or Denial-of-Service of the antivirus engine process. This issue affects Avira Antivirus on Windows, macOS, and Linux for engine builds before 8.3.27.12.

Published

Date2026-06-12

Updated

Date2026-06-12

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

https://www.gendigital.com/us/en/contact-us/security-advisories/

CVE-2026-12068

SUMMARY

Information disclosure vulnerability in Avira Password Manager when used with Mozilla Firefox may allow a remote attacker operating a cross-origin iframe to obtain credentials autofilled for the parent web page via incorrect autofill field selection. This issue affects Avira Password Manager when used with Mozilla Firefox on Windows, macOS, and Linux.

Published

Date2026-06-12

Updated

Date2026-06-12

RISK INFORMATION (Score: 7.4)

cvss3

Base Score: 7.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:N/A:N

Impact Score

Exploitability

2.8

REFERENCES

https://www.gendigital.com/us/en/contact-us/security-advisories/

CVE-2025-9033

SUMMARY

Heap buffer out-of-bounds read vulnerability in Avira Antivirus engine when scanning a malformed PDF file may allow Local Execution of Code or Denial-of-Service of the antivirus engine process. This issue affects Avira Antivirus on Windows, macOS, and Linux for engine builds before 8.3.70.76.

Published

Date2026-06-12

Updated

Date2026-06-12

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

https://www.gendigital.com/us/en/contact-us/security-advisories/

CVE-2025-9032

SUMMARY

Heap buffer out-of-bounds read vulnerability in Avira Antivirus engine when scanning a malformed Windows PE file may allow Local Execution of Code or Denial-of-Service of the antivirus engine process. This issue affects Avira Antivirus on Windows, macOS, and Linux for engine builds before 8.3.70.98.

Published

Date2026-06-12

Updated

Date2026-06-12

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

https://www.gendigital.com/us/en/contact-us/security-advisories/

CVE-2025-14098

SUMMARY

Heap buffer out-of-bounds write vulnerability due to integer overflow in Avira Antivirus engine when scanning a malformed MS-DOS executable file may allow Local Execution of Code or Denial-of-Service of the antivirus engine process. This issue affects Avira Antivirus on Windows, macOS, and Linux for engine builds before 8.3.70.104.

Published

Date2026-06-12

Updated

Date2026-06-12

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

https://www.gendigital.com/us/en/contact-us/security-advisories/

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…